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Abstract
Salivary gland diseases in children are rare, apart from viral-induced
diseases. Nevertheless, it is essential for the otolaryngologist to recog-
Heinrich Iro1
Johannes Zenk1nize these uncommon findings in children and adolescents and to diag-
nose and initiate the proper treatment.
The present work provides an overview of the entire spectrum of con-
genital and acquired diseases of the salivary glands in childhood and
1 Department of
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and Neck Surgery, Universityadolescence. The current literature was reviewed and the results dis-
cussed and summarized. Hospital Erlangen, University
of Erlangen-Nuremberg,
GermanyBesides congenital diseases of the salivary glands in children, themain
etiologies of viral and bacterial infections, autoimmune diseases and
tumors of the salivary glands were considered. In addition to the known
facts, new developments in diagnostics, imaging and therapy, including
sialendoscopy in obstructive diseases and chronic recurrent juvenile
sialadenitis were taken into account. In addition, systemic causes of
salivary gland swelling and the treatment of sialorrhoea were discussed.
Although salivary gland diseases in children are usually included in the
pathology of the adult, they differ in their incidence and sometimes in
their symptoms. Clinical diagnostics and especially the surgical treat-
ment are influenced by a stringent indications and a less invasive
strategy. Due to the rarity of tumors of the salivary glands in children,
it is recommended to treat them in a specialized center with greater
surgical experience.
Altogether the knowledge of the differential diagnoses in salivary gland
diseases in children is important for otolaryngologists, to indicate the
proper therapeutic approach.
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1 Embryology and anatomy of the
salivary glands
The three major paired salivary glands (parotid gland,
submandibular gland and sublingual gland) and the
700–1,000 minor salivary glands of the oral cavity and
pharynx all come from the ectodermal germ layer. They
start to appear between the sixth and tenth week of em-
bryogenesis from cell accumulations in the embryonic
foregut, with the common structural development of acini
and excretory ducts. The ducts develop in parallel and
have a patent lumen from the 22ndweek onwards. During
their growth in the surrounding mesenchymal tissue,
lymphatic tissue remains within the glandular structures,
especially in the case of the parotid glands. And precisely
this is the reason for salivary gland involvement in certain
diseases of the lymphatic system (e.g. viral infections,
inflammation, and lymphomas). After birth, the glands
gradually increase in size until adulthood.
The parotid gland is the largest of the salivary glands. Its
5–6 cm long excretory duct (parotid duct; Stensen’s duct)
crosses the masseter muscle, curves medially and then
penetrates the buccinatormuscle and the buccalmucosa
to open into the vestibule of the mouth opposite the
second upper molar. On average, the diameter of the
parotid duct is 1.4 mm at the hilum, 1.2 mm as it runs
through the buccinator and 0.5 mm at the ostium [1].
The body of the gland, which consists of serous lobules,
lies in the retromandibular fossa, above and posterior to
the masseter muscle and the lower jaw. It is important
to remember that the facial nerve in children lies much
more laterally than in adults, as the mastoid cells are not
yet fully developed. In young children, the nerve is even
a little larger in proportion to the surrounding structures
[2], [3].
The seromucous submandibular gland lies on the hyo-
glossal muscle between the anterior and posterior bellies
of the digastric muscle. The 5–6 cm long submandibular
duct passes around the mylohyoid muscle, crosses the
lingual nerve and then crosses the floor of the mouth to
open through the sublingual caruncle. The average dia-
meter of the duct is 1.5 mm along its entire course from
hilum to ostium, narrowing to 0.5 mm at the ostium itself
[1]. The sublingual gland, a mucoserous gland, lies in the
sublingual fossa, in submucosal tissue superior to the
mylohyoid muscle. Its excretory duct either empties into
the submandibular duct or opens separately into the oral
cavity on the salivary papilla [4]. There are no estimates
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of duct length or diameter in childhood to be found in the
literature.
2 Physiology of the salivary glands
Healthy adults produce about 1.5 litres of saliva a day.
Some 20–25% comes from the parotid gland, about
70–75% from the submandibular gland and 5% from the
sublingual gland. The viscosity of the saliva depends on
the individual proportions secreted by the different glands
[5].
Taking the total production from all of the salivary glands,
0.3 to 0.5ml of saliva is secreted perminute at rest, while
1.5 ml/min is produced under conditions of maximum
stimulation. Hidas et al. [6] studied salivary flow in chil-
dren and adolescents with attention deficit hyperactivity
disorder (ADHD). The rate of total salivation at rest was
1.1 ml/min in the control group and therefore similar to
the recognised normal values, while the flow rate in pa-
tients with ADHD with or without medication was signific-
antly lower. Continuous secretion is activated by a weak
parasympathetic stimulus and is important in keeping
themouthmoist. Central nervous system (CNS) regulation
arises in the salivary nuclei of the medulla and pons and
is transmitted via the autonomic nervous system. The
major salivary glands are innervated by both parasympa-
thetic and sympathetic nerves. However, unlike in other
organs, they do not act antagonistically to each other.
Both systems stimulate saliva secretion, albeit in different
ways. Parasympathetic stimuli lead to the rapid produc-
tion of a copious watery secretion that is rich in enzymes.
At the same time, there is vasodilatation. In contrast,
sympathetic stimulation induces the secretion of a
smaller quantity of slimy viscous saliva associated with
vasoconstriction. The salivary centre may be affected by
external factors acting though higher CNS centres (the
sight, smell or thought of food). Two reflexes are involved:
a simple unconditioned reflex and an acquired condi-
tioned reflex. The simple reflex is triggered by oral
chemoreceptors and baroreceptors.
The parasympathetic component stimulates saliva secre-
tion at the receptor level. Muscarinic receptors are import-
ant here, also in the pharmacotherapy of functional dis-
orders. In addition, dehydration, lack of sleep and anxiety
may inhibit saliva production.
Saliva consists of up to 99.5%water. Protein, electrolytes,
and various bactericidal and antimicrobial factors make
up just 0.5%. Roughly speaking, two characteristic
secretory compartments can be distinguished: the first
is the fluid serous saliva, which contains bactericidal
substances such as thiocyanate, proteolytic enzymes
(lysozyme) and antibodies such as IgA, as well as α-
amylase to digest starches, while the second is themucus
secretion or the mucous component of saliva, which
prevents the oral mucosa from drying out and makes
chewing and swallowing considerably easier. It also im-
proves the sense of taste and clarity of speech [5].
A continuous flow of saliva with this composition protects
against wound infections and caries. Bacteria and food
residues are washed away, so to speak. Calcium phos-
phate ions contribute to the remineralisation of the teeth.
The bicarbonate in saliva acts as a buffer for acids from
food and bacterial metabolism and this also helps to
prevent tooth decay. The pH is higher with an increased
salivary flow and this may possibly protect the oesopha-
geal mucosa by buffering any acid reflux. Recent studies
also credit saliva with an effect on the gland itself, at least
a paracrine one (e.g. leptin) [7]. In a comparative study
of the minor salivary glands, Sonneson demonstrated
that even in preschool children, a high density of glands
andmature innate immunity existed, which further adapts
as the children grow up [8]. Studies on children’s saliva
are particularly relevant to dental problems. It appears
that the quality (protein content) rather than the quantity
of saliva is important for caries prophylaxis. In a group of
four- to six-year-olds, Bhalla et al. showed that tooth decay
was inversely proportional to the proline content, but not
to the total quantity of saliva produced [9]. Medicines
used for oral asthma therapy, such as β2-agonists and
cortisone, may reduce salivation [10]. A protein-deficient
diet or chemotherapy for cancer during childhood even
leads to a persistent functional impairment of the salivary
glands, which may have lasting effects on the immune
defences in the adult and be associated with significantly
greater pathological conditions of the teeth [11], [12].
3 Clinical examination and imaging
A careful history is the first decisive step in the diagnosis
of salivary gland conditions. In infants and young children
it is, of course, extremely important to question the par-
ents. As with adult patients, a relatively small number of
cardinal symptoms are to be found for a large number of
possible diagnoses.Most conditions affecting the salivary
glands give rise to painful or painless swelling of the
gland. In addition, there may be xerostomia (dry mouth),
sialorrhoea (drooling) and facial palsy and, of course,
corresponding generalised symptoms whenever there is
an infection. The differential diagnosis to be considered
in children includes infections of the salivary glands,
autoimmune and systemic diseases and lymphadeno-
pathy of various origins. Tumours and drug-induced dis-
orders tend to be rare. Clinical examination often provides
a first provisional diagnosis, for example, a ranula can
easily be identified on inspection. Assessment of the
saliva being secreted also indicates whether there is an
acute suppurative infection (creamy yellow) or a more
chronic recurrent process (flocculent secretion). Salivary
stones and tumours can also usually be palpated. Imaging
or laboratory tests are usually required to define the
condition and sometimes confirm the diagnosis. ENT
surgeons in Germany are fortunate to have ultrasound
scanning available as an excellent method for assessing
the three major paired salivary glands in children. As the
required depth of penetration is small, frequencies of
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7.5–12 MHz are suitable for scanning children to depict
and anatomically classify infections, stones and tumours
as well as lymph nodes. The salivary gland ducts
(Stensen’s and Wharton’s ducts) can only be seen when
an obstructive disease or an acute suppurative infection
is present, either on initial examination or secondary to
a secretory stimulus (vitamin C). Colour Doppler mode
allows the internal perfusion of space-occupying lesions,
the circulation in the glands themselves and non-perfused
cysts to be identified. This helps to characterise lesions
more precisely, especially haemangiomas and arterioven-
ous malformations. Conventional sialography and X-rays
have no place in diagnostic investigations during child-
hood. In young children, sialography can anyway only be
performed under sedation. Magnetic resonance imaging
(MRI) and computed tomography (CT) are reserved for
certain situations requiring the further workup of space-
occupying lesions or processes that exceed the ultrasono-
graphic limits of the salivary glands and extend into the
para- or retropharyngeal spaces or to the base of the skull
or mastoid. MRI focuses mainly on questions of soft tis-
sue, nerves and dural infiltration, while MR sialography
may be used to examine the ducts or MR angiography to
demonstrate the topography of the vascular supply. On
the other hand, CT scans can be used to assess bony
structures and is also useful for determining the extent
of large abscesses, especially in the para- and retropharyn-
geal spaces. Sialendoscopy, with its direct visualisation
of the ducts, can fill any diagnostic gaps in obstructive
salivary gland disease.
Fine needle aspiration biopsy can be used to obtain tissue
for ascertaining the type of tumour and whether it is be-
nign or malignant andmaterial for further microbiological
investigation in the case of infection. It is important to
detect the pathogen by direct means or by polymerase
chain reaction (PCR). Indications for fine needle aspiration
are limited in children and must be considered very
carefully, as the procedure usually requires general an-
aesthesia. Depending on the indication, an open biopsy
or complete resection of a space-occupying mass can be
performed for histology. The workup of an infection/in-
flammation includes, of course, a full or differential blood
count and C-reactive protein or procalcitonin (in cases of
sepsis). Antinuclear antibodies (ANAs), SS-A or SS-B
(Sjögren’s syndrome antibodies to duct epithelium,
formerly Ro and La) and angiotensin converting enzyme
(ACE) levels may be indicated in rare childhood systemic
diseases such as Sjögren’s syndrome or sarcoidosis. The
determination of the salivary secretion rate is only of
secondary importance in childhood.
4 Congenital salivary gland
diseases
Apart from conditions that affect the saliva composition
(e.g. sticky saliva in Prader-Willi syndrome) or cause an
inability to swallow and lead to drooling (see below), hy-
poplasia or aplasia of the salivary glands is a rare occur-
rence and can affect just one, several or even all of the
salivary glands. Aplasia of the salivary glands may occur
in isolation or be associated with other malformations of
the first branchial arch. These include hemifacial micro-
somy, Treacher Collins syndrome and other congenital
malformations of the face.
A recent study from Norway looked at 21 patients with
Treacher Collins syndrome [13]. In addition to ultrasound
scans, it analysed salivary secretion. Almost half (48%)
of the patients had abnormalities of the salivary glands.
The pathology included dysplasia in six cases and aplasia
in four. The salivary secretion rate was reduced in almost
all the patients, although there was no correlation with
subjective or ultrasound findings.
Matsuda et al. reviewed 43 cases of salivary gland aplasia
appearing in the literature since the first case was report-
ed by Gruber in 1885 [14], [15]. Nineteen more cases
have been reported since 1999, of which at least five
exhibited bilateral aplasia of the lower jaw and parotid
gland [16]. A few of the case reports show a combination
of aplasia and hypofunction of the salivary glands with
other ectodermal malformations of the tear passages,
skin appendages, and teeth. A familiar form seems to be
inherited as an autosomal dominant with great variability
of the phenotype [17]. One of the best-known conditions
is the lacrimo-auriculo-dento-digital (LADD) syndrome,
characterised by malformations including aplasia of the
tear ducts, aplasia of the salivary glands, deafness and
malformations of the ear as well as abnormalities of the
teeth and limbs. Hypoplasia or aplasia of the salivary
glands is often not recognised until late, since these pa-
tients, unlike those with acquired xerostomia, do not
complain of their symptoms. Patients usually present with
massive tooth decay associated with a dry mouth, diffi-
culty swallowing and drinking copious amounts of fluid.
Early diagnosis (on clinical examination, ultrasound, MRI
and possibly scintigraphy) can result in appropriate and
early prophylaxis against sequelae (teeth) and consider-
able relief of the symptoms.
And finally, juvenile recurrent parotitis may also be viewed
as a genetic malformation of the gland [18]. Because of
its topicality and new information on the treatment of this
condition, it will be addressed in a separate section (see
5.2.8).
Polycystic (dysgenetic) disease of the parotid gland was
described von Seifert et al. (1981) as a very rare entity
that is independent of recurrent parotitis and congenital
sialectasis [19]. They reported the case of a six-year-old
girl who, like her father, suffered from this condition and
therefore assumed an autosomal dominant inheritance.
The cause is thought to be a defect in the interactions
between activin, follistatin and TGF-β, leading to a devel-
opmental disorder of glandular tissue (salivary glands,
pancreas and kidneys) in the mouse model [20].
Ranulas, benign tumours of the sublingual gland, may
already occur before birth and large ones can cause direct
respiratory problems during and after delivery. A congen-
ital defect in the mylohyoid muscle is discussed in con-
nection with plunging ranulas. These lesions have been
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observed in siblings and are more common in certain
ethnic groups [21], [22], [23]. An ex utero intrapartum
treatment (EXIT) procedure can be carried out electively
in such a situation that could possibly even be life-
threatening. During a caesarean section, the ranula is
decompressed and the airways held open before the
umbilical cord is cut. Only then is delivery completed [24].
Only 5% of all salivary gland tumours occur in childhood.
Congenital tumours such as sialoblastomas are even less
common [25], [26]. The difficulty in the histological
diagnosis has led to various synonyms being used in the
literature, depending on the cell type: embryoma, congen-
ital basal cell adenoma, etc. As a rule, tumours arise in
the perinatal period or can already be identified on ultra-
sound scans during pregnancy. The parotid and sub-
mandibular glands are most often affected. Histology
shows sialoblastomas to be malignant tumours arising
from the embryonic epithelial anlage and they show a
wide range of differentiation. These tumours were first
described in 1966 [27]. Up to 2010, a further 26 cases
were reported in the literature, which have occasionally
also been associated with hamartomas or hepato-
blastomas [28]. T1-weighted MRI shows an isointense
tumour with heterogeneous contrast enrichment. A high
mitosis rate, necrosis and anaplasia on histology are
considered to be unfavourable prognostic features [29].
The treatment of choice is complete resection of the tu-
mour, although this is not always possible because of
infiltration into the surrounding structures, including the
base of the skull. Tumour residues usually respond well
to adjuvant chemotherapy or in cases that have already
metastasised, to neo-adjuvant chemotherapy [30]. As for
rhabdomyosarcomas, several courses of treatment are
given (e.g. ifosfamide 3 g/m2/day on days 1 and 2; vin-
cristine 1.5 g/m2 on day 1; actinomycin D 1.5 g/m2 on
day 1; doxorubicin 30 mg/m2/day on days 1 and 2) [31].
Radiotherapy at this age is associated with possible ad-
verse effects on bone growth and not inconsiderable
mutagenicity.
Local recurrence was described in 10 of the 26 cases
reported, so that patients should be monitored closely.
At an average follow-up of 46 months (10 days to
43 years), 18 patients (69%) were still alive. Thus the
prognosis is still relatively good [28].
5 Salivary gland infection/
inflammation
Inflammatory diseases are the most common conditions
besides benign tumours that affect the salivary glands
of children and adolescents [32]. The most important
viral pathogens are themumps virus and cytomegalovirus
[33], which will be looked at in more detail in the following
section. In addition, there are acute bacterial infections
and chronic inflammation, as well as autoimmune dis-
eases. It must also be mentioned that the saliva itself
plays an important role in many more viral, bacterial and
other diseases. The paper presented by Weidauer to the
72nd annual meeting of the German Society of Otorhino-
laryngology, Head and Neck Surgery in Hamburg is of
particular interest in this context [34]. According to this
presentation, saliva is a reservoir of the microorganisms
involved in persistent bacterial infections of the oral
cavity (dental plaque), as well as of the normal oral flora
with pathogenic potential, and a vector for Helicobacter
pylori. In certain infections, viruses and bacteria can be
demonstrated in the saliva for a long time, even without
any symptoms (mumps, cytomegalovirus, human herpes
viruses, HIV, rabies, hepatitis B) or are found only transi-
ently (pertussis, diphtheria, Haemophilus influenzae,
Epstein-Barr virus, adenoviruses, herpes simplex virus
type 1, influenza and parainfluenza viruses, measles and
rubella viruses). Organismswith oncogenic potential, such
as Epstein-Barr virus, human herpes virus 8, human




The mumps virus is an encapsulated RNA virus (15,384
nucleotides) of the paramyxovirus family, with a diameter
of 200 nm. The RNA codes for six structural proteins and
at least two other proteins. The capsule consists of a two-
layered lipid membrane, which means that the virus is
susceptible to disinfection with ether or alcohol. The virus
is stable for several days at 4°C [35]. So far, twelve
genotypes (A–L) of themumps virus have been identified,
with different regional distributions [36]. The disease is
transmitted by droplet or contact spread. The incubation
period is 15–24 days. Patients are already infectious two
days before the onset of symptoms [37]. The virus can
be detected in the saliva for seven days before the start
of symptoms and for nine days afterwards. Virus replica-
tion usually takes place in the upper respiratory tract and
in the salivary glands. Nevertheless, parotitis is not one
of the first or even essential steps in the course of the
infection. Replication takes place in the duct epithelium
of the parotid gland and leads to oedema and a local in-
flammatory reaction with lymphocyte and macrophage
infiltration [38].
About one-third of mumps infections are asymptomatic.
The cardinal symptoms of parotitis with fever are seen in
60–70% of all infections and in 95% of symptomatic pa-
tients. The gland remains swollen for about one week.
There is bilateral involvement in 90%, although the
swellingmay not be seen at the same time on both sides.
Complications of parotitis are rare: sialectasis with further
recurrent swelling has been reported [39]. The sub-
mandibular and sublingual glands may also be involved
in 10% of cases. Problems with lymphatic drainage may
cause bilateral cervical oedema or, in rare cases, supra-
glottic oedema [40]. The disease can also spread to other
organs, giving rise to epididymitis in 30% and bilateral
orchitis also in up to 30%. Infertility as a result of mumps
infection is, however, a rare complication [41]. Oophoritis
4/30GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2014, Vol. 13, ISSN 1865-1011
Iro et al.: Salivary gland diseases in children
is seen in 5%, mumps meningitis in up to 10% and en-
cephalitis in up to 1% of those infected. Typical symptoms
of encephalitis are seizures, clouding of consciousness
and focal neurological symptoms such as ataxia, dizziness
and behavioural disorders, while EEG changes are ob-
served in children [42]. Themortality of encephalitis may
be as high as 5%. Transient high frequency hearing loss
has been observed in up to 4% of cases [43]. Persistent,
usually unilateral, deafness occurs in 0.005%, i.e. one in
20,000 patients [44]. Infection in the first trimester of
pregnancy is particularly problematic. It is estimated that
up to 27% of cases end in spontaneous abortion. Pancre-
atitis occurs in about 4% of people with mumps. The
complications of mumps increase, above all, with age
[38].
The diagnosis is made on the basis of the clinical history
and symptoms, and confirmed by elevated serum levels
of IgM antibody to the mumps virus (with an ELISA), al-
though it should be noted that false negative results occur
in up to 30% of cases [45]. The false negative rate can
be reduced by performing the test four days after the
onset of symptoms. Virus may also be demonstrated dir-
ectly in certain cases, but only during the first few days
of infection, or by RT-PCR. The differential diagnosis in-
cludes infection with EBV, parainfluenza viruses, adeno-
viruses or human herpes virus 6 [46] and, of course, all
other causes of salivary gland enlargement.
As the disease is benign and usually self-limiting, treat-
ment is purely symptomatic. The administration of immun-
oglobulins may be considered in isolated cases. Treat-
ment success has been reported in presumed autoim-
mune sequelae such as postinfective encephalitis, Guil-
lain-Barré syndrome and idiopathic thrombocytopenic
purpura [47], [48], [49].
The incidence of mumps in Germany shows that it is still
endemic despite the long-established vaccination pro-
gramme (in West Germany since 1976 and throughout
the whole country since 1991). Even so, thanks to the
vaccine, the incidence has fallen from 100–1,000 cases
per 100,000 inhabitants in the pre-vaccine era to 10.3
per 100,000 inhabitants in the period 2007–2011 [50].
However, despite the two-dose vaccine introduced in
1991, seroconversion could not be detected in 20–22%
of the 0–17 age group. This may be due to the fact that
some parents no longer have their children vaccinated
or that secondary immunisation is suppressed because
of a lack of circulating wild types. There also seems to be
an increasing incidence, particularly in 20- to 29-year-
olds in the Western federal states, as was seen in a large
outbreak in Bavaria in 2010/11, which mainly affected
people aged 15–29. Even if mumps has become less
common because of the vaccine, it is still important for
ENT surgeons to consider it in the differential diagnosis
of salivary gland swellings.
5.1.2 Cytomegalovirus
Cytomegalovirus is a member of the herpes virus family.
The infection rate in the population is 40% to 100% [51].
Up to 20% of children come into contact with the virus
even before puberty. Reinfection may occur with genetic-
ally different pathogenic strains [52]. The primary infec-
tion is often unnoticed, but the virus may lie dormant in
the body and cause symptomswhen there is an alteration
of the immune defences. The infection is transmitted by
direct contact with various bodily fluids, including saliva.
Serious complications may be associated with neonatal
infection from the birth canal and reactivation in immun-
osuppressed patients or following organ transplantation.
Immunocompetent patients may show a clinical picture
similar to that of infectious mononucleosis with all its re-
cognised symptoms. Hepatitis, Guillain-Barre syndrome,
encephalitis, pneumonia and myocarditis are very rare.
The diagnosis is confirmed by demonstrating IgM or by
PCR. Treatment is purely symptomatic. It is important to
consider the possibility of reactivation in immunocom-
promised patients. Furthermore, seronegative pregnant
women should keep away from potentially infectious
people because of the risk of intrauterine CMV infection
of the fetus with possibly severe brain damage and vis-
ceral disease [53].
5.1.3 HIV and the salivary glands
HIV infections may also primarily involve the salivary
glands, especially the parotid. The clinical picture is often
one of unilateral swelling, pain and inflammatory changes
in the gland, sometimes analogous to acute parotitis. On
the other hand, theremay just be a painless enlargement
of the gland. Ultrasound scans show hypoechoic and an-
echoic structures, which correspond histologically to epi-
thelial cysts and lymph nodes. In these cases, HIV testing
should be added to the diagnostic tests and further
cytological or histological workup considered [54]. Hobbs
et al. suggested a three-stage classification in paediatric
patients: persistent generalised lymphadenopathy (PGL),
benign lymphoepithelial lesions (BLEL) and benign
lymphoepithelial cysts (BLEC) [55]. Benign lymphoepitheli-
al lesions in HIV are similar to those in other salivary gland
diseases (sarcoidosis, Sjögren’s syndrome, chronic recur-
rent parotitis) and are probably the expression of an
autoimmune reaction [56]. Whilst BLEL is thought to be
a separate histological entity with no transformation into
BLEC, the generalised lymphadenopathy is probably the
precursor of BLEC. The management of benign lympho-
epithelial cysts includes a watch and wait policy, repeated
fine-needle aspiration (also to confirm the diagnosis) or
drainage, highly active anti-retroviral therapy (HAART)
[57], [58], [59], sclerotherapy (ethanol, picibanil, tetracyc-
line, doxycycline, etc.), radiotherapy (8–24Gy) and surgery
with extracapsular dissection or total parotidectomy [60].
The choice of treatment must be determined on a case-
by-case basis, especially for paediatric patients, but an
initial monitoring with appropriate antiretroviral medica-
tion would appear to be possible in most cases. Radio-
therapy and surgery are indicated in selected cases [55].
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5.2 Bacterial sialadenitis in childhood
5.2.1 Neonatal suppurative parotitis
Neonatal suppurative parotitis has been described as a
particular form of acute sialadenitis occurring immediately
after birth. There is typically a warm red swelling around
the affected gland. In a recent review, Ismail et al. collect-
ed 44 cases reported in the literature since 1970 [61].
The infection was unilateral in 77% and a similar percent-
age of the affected patients were boys. Purulent secre-
tions were expressed from the papilla of the parotid duct
in all but two patients. Only half of the patients had a
raised temperature. The leucocyte count was elevated in
44%. Other laboratory tests were not particularly helpful.
The organisms isolated were Staphylococcus aureus (in
61% of cases), with three patients (7%) having MRSA
(methicillin resistant staphylococcus aureus) [62], other
Gram-positive cocci (25%), Gram-negative rods (16%)
and anaerobic bacteria (11%). Blood cultures were posi-
tive in 32%.
Possible modes of infection are bacteria ascending via
the parotid duct and haematogenous spread. As the
number of breast-fed children (78%) in this group was
considerable higher than average, it was suggested that
infants became dehydrated through inadequate breast-
feeding, with ascending duct infection related to de-
creased salivary flow [63]. Other risk factors were high
ambient temperatures, excessive sucking and feeding
via a nasogastric tube [64]. In addition, the rate was
considerably higher in premature babies (32%) than
otherwise described. Premature birth is therefore a risk
factor [65]. Themajority of the patients were successfully
treated with a combination of an anti-staphylococcal drug
and an aminoglycoside or a third-generation cephalospor-
in. The duration of antibiotic therapy was between seven
and 21 days, depending on the bacterial colonisation,
comorbidity and spread of infection. Only 23% required
surgical drainage. Most patients have an excellent pro-
gnosis with respect to morbidity and mortality; as a rule,
it is very favourable. Parotid fistulas, facial nerve palsy,
septicaemia, meningitis or mediastinitis occur only rarely
[66].
5.2.2 Suppurative parotitis and parotid
abscesses in children and adolescents
Older children and adolescents very rarely have suppura-
tive sialadenitis. In a centre for paediatric ENT, Stong et
al. treated only 17 patients with acute suppurative parot-
itis, and a further four patients with an acute exacerbation
of juvenile recurrent parotitis, over a period of five years
[67]. It must be assumed that most children with these
conditions are treated by their general practitioners or in
an ENT practice. The mean age of the eight boys and
13 girls was 6.5 years (6 months to 15 years). Typical
symptoms were painful unilateral or bilateral swollen
parotid glands and purulent secretion from the parotid
duct; 62% of the patients had to be admitted to hospital
with severe dehydration, leucocytosis and fever. Over half
of the children admitted had serious comorbidities (cystic
fibrosis, leukaemia, HIV, diabetes and infantile cerebral
palsy). In two (10%) patients, an abscess developed in
the gland during the course of the disease.
Treatment of acute suppurative parotitis consists of gland
massage, sialagogues and antibiotic therapy to cover
staphylococci and streptococci, in particular. Antibiotic
resistance testing is only needed in cases of treatment
failure. Ultrasound scanning is the imaging method of
choice to perform after clinical examination. CT is rarely
indicated, but may be used to determine the extent of an
abscess. Apart from abscesses, the complications of
acute parotitis include facial palsy and extensive phleg-
mons of the throat causing difficulty in breathing [68].
Parotidectomy is required only in rare cases [32]. Saar-
inen et al. from Finland reported on ten children (aged
2–16 years) who were treated within a ten-year period
and calculated an incidence of 0.7 cases per million in-
habitants [69]. The treatment of choice was incision and
drainage of the abscess (Figure 1). Considerations in the
differential diagnosis of an abscess include infected cysts
or fistulas of the first branchial arch. Even though the
most common pathogens comprise a mixed flora of sta-
phylococci, streptococci, anaerobic bacteria and Haemo-
philus influenzae [70], the possibility of tuberculosis and
atypical mycobacterial infections should also be con-
sidered [71]. Samples should therefore be obtained be-
fore treatment and sent for microbiological tests. Salivary
stones should also be ruled out.
5.2.3 Obstructive sialadenitis in childhood
Also in childhood are stones frequently the cause of ob-
struction in the excretory ducts. As a rule, idiopathic in-
flammatory stenosis and radioiodine-induced stenosis
are found only in adults [72], [73], [74], [75], [76], [77],
[78]. In our own patient population, we have also seen
iatrogenic stenosis after surgical procedures on a frenu-
lum of the tongue or ranula. One adolescent patient had
traumatic papillary stenosis of the parotid duct, which is
rarely seen in children and adolescents, but caused in
this case by excessive bruxism. Salivary stone disease is
seldom seen in children [79]. In their literature review of
reports published since 1860, Reuther and Hausamen
found 21 cases of submandibular gland stones in children
aged between three weeks and 15 years [80]. In Japan,
thirty-two cases in children below the age of ten were
described up to 1994; in 29 of them, stones had formed
in the submandibular gland [81].
In their study population, Zenk et al. described 39 patients
below the age of 21. The youngest patients with con-
firmed stones in the parotid gland were a five-year-old
girl and a three-year-old boy. Parotid stones are less
common in adults as well [82].
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Figure 1: a) Three-year-old boy with a painful red swelling of
the right cheek since 3 days. b) No improvement on antibiotics.
Axial ultrasound scan shows a hypoechoic, poorly demarcated,
inhomogeneous lesion, measuring 21 mm x 16 mm (+…+), in
the parotid gland, consistent with the diagnosis of an abscess.
c) Treatment of choice was drainage of the abscess under
general anaesthetic, with irrigation and insertion of a wick.
Blue line: the mandible.
As in adults, the symptoms are characteristic. There is
usually recurrent swelling of the affected gland, which
may be associated with pain. Sialolithiasis may also
present for the first time as an acute bacterial infection
of the gland. Management priorities are treating the si-
aladenitis and looking for the stone. The treatment of
salivary stones in children today is basically not different
from that in adults. As a rule, younger children require a
general anaesthetic for the procedure because they are
unable to cooperate. The decisive factors in selecting the
therapeutic option are the site size, and mobility of the
stone.
Sialendoscopy can be used initially to investigate both
the parotid and submandibular ducts to determine the
presence of amobile stone, or one that can bemobilised,
in the distal duct system and right up to the hilum
(Figure 2). In this case, the stone can then be extracted
using a Dormia basket [83], [84].
Stones that have impacted anywhere up to the hilum in
the submandibular gland can usually be removed
transorally without problem [85] (Figure 3). Extracorporeal
shockwave lithotripsy (ESWL) is an excellent method for
disintegrating or destroying impacted parotid stones, irre-
spective of their site and size. The stone fragments may
pass spontaneously or a repeated attempt can be made
to remove the stone endoscopically [86], [87], [88]. ESWL
is also suitable for use in children (Figure 4). A combined
endoscopic and transcutaneous approach to stone remov-
al can be used as an alternative [89]. Lithotripsy is also
indicated for submandibular stones lying proximally. New
intracorporeal methods with laser lithotripsy have been
reported in a few adult study populations, but have not
yet become established in routine clinical practice, partly
because of possible adverse effects and partly because
they are time-consuming and relatively expensive [90].
If it is not possible to relieve the symptoms with these
methods, then the only remaining option is surgical ex-
cision of the gland with all its known risks [91], [92].
5.2.4. Pneumoparotitis
Idiopathic recurrent pneumoparotitis is a rare condition
with painful swelling of the affected gland [93]. In this
case, patients blow air into the excretory ducts of the
parotid gland. It has been described in wind instrument
players and glass blowers [94]. However, it can also be
associated with diving, dental treatment or recovery from
an anaesthetic (coughing fits) [95]. It may also be self-
induced in adolescents with psychosocial disorders [96].
It remains unclear whether the cause involves an open
parotid duct ostium or a weak buccinator muscle in
combination with already dilated ducts. We ourselves can
report on a 13-year-old boy who developed the recurrent
parotid swelling of pneumoparotitis as a result of blowing
up balloons. The diagnosis ismade using ultrasonography
(Figure 5), where numerous mobile echogenic reflexes
with a comet-tail artefact are apparent. The air inclusions
can also be seen clearly on CT. Available treatment in-
cludes symptomatic measures such as gland massage,
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Figure 2: Sialendoscopy performed on a 13-year-old girl to detect a stone in the hilum of the right submandibular gland (see
screen) that could not be clearly demonstrated with ultrasound scanning.
Figure 3: a) Ultrasound scan showing two hilar stones, measuring 4.4 mm and 4.7 mm, in the left submandibular gland of
14-year-old girl, before treatment. The hypoechoic changes in the parenchyma of the gland are regarded as the expression of
chronic obstruction. b) Transoral stone extraction with marsupialisation of the duct under local anaesthetic in the same patient.
c) Four months after the stone extraction, the patient is free of symptoms and has no new stones. The ultrasound scan shows
a normal gland parenchyma (MMH: mylohyoid muscle, GSM LI: left submandibular gland). d) A neo-ostium with no signs of
inflammation can be seen in the left posterior floor of the mouth.
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Figure 4: a) Pre-operative ultrasound scan of a 5-year-old girl with a stone measuring almost 9 mm (+…+) in the right parotid
gland (DS: Stensen’s duct; GP: parotid gland; UK: lower jaw; MM: masseter muscle). b) Extracorporeal shockwave therapy under
general anaesthetic. c) No stones or symptoms one year after the intervention, with an unremarkable ultrasound appearance
of the right parotid gland. d) A 3-year-old boy after lithotripsy of a stone in the left parotid, showing petechial haemorrhages
into the skin as a typical adverse effect of lithotripsy. These will be resorbed within a few days.
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sialagogues, analgesics and antibiotic therapy, if neces-
sary. The most important thing is to avoid the underlying
trigger. Psychiatric treatment or behavioural therapy
should also be considered for patients with self-induced
disease. Surgical procedures such as duct ligation, duct
repositioning into the tonsillar fossa and even excision
of the gland have been described, but are indicated only
in exceptional cases [97], [98].
Figure 5: Sonographic imaging in an 11-year-old boy with
recurrent pneumoparotitis after blowing up balloons with
mobile hyperechoic reflections with acoustic shadowing
(LUFT=AIR), which correspond to air inclusions in the duct
system (MM: masseter muscle, UK: lower jaw, GP: parotid
gland).
5.2.5. Postoperative sialadenitis
Unilateral parotid gland swelling arising immediately
postoperatively (sometimes called ‘anaesthesiamumps’)
usually resolves spontaneously within 48 hours [99] and
can also rarely occur in children. The incidence is one
patient in 1,000–3,000 surgical procedures. The under-
lying cause is thought to be an imbalance between secre-
tion and obstruction [100], [101]. Dehydration and intra-
operative medication, the duration of the operation and
the positioning of the head are all thought to play a part
[102].
5.2.6 Tuberculosis (TB) andmycobacteria other
than tuberculosis (MOTT)
Infection with mycobacteria is particularly relevant to the
parotid gland and worth mentioning once again here,
since from both an anatomical and developmental point
of view, this gland contains numerous lymph nodes, which
correlate with disease. On the other hand, the disease
may spread from the cervical lymph nodes to the salivary
glands. The incidence of tuberculosis is falling in de-
veloped countries, but infections with MOTT are on the
increase [103]. In children, the incidence is 7.7 permillion
inhabitants up to the age of 18 and as high as 23 per
million inhabitants up to the age of four [104]. The chil-
dren are usually otherwise healthy. Other risk groups for
atypical mycobacterial infections are immunosuppressed
patients [105]. The typical clinical picture is of unilateral,
usually hard, enlargement of the intraglandular lymph
nodes without any other signs of illness. These masses
may spontaneously form fistulas and persist for months
or even years. Even without any treatment, the lesions
regress with time [106]. Diagnostic investigation is based
on ultrasonography (Figure 6) and the microbiological
verification of the pathogenic organism (cultures, acid-
fast rods seen on microscopy and PCR). The literature
offers different therapeutic options: surgical excision of
affected lymph nodes, pharmacotherapy or even a watch
and wait policy with clinical monitoring [107]. The choice
of therapy involves weighing up the extent to which the
disease is affecting the patient against the possible ad-
verse effects and complications of surgical treatment or
medication.
Figure 6: Ultrasound scan of an atypicalmycobacterial infection
in the inferior pole of the left parotid gland (RF +…+), prior to
surgical excision, in a 2-year-old girl (MSCM:
sternocleidomastoid muscle; GLP: parotid gland).
A prospective study showed that simple incision and
drainage more often led to postoperative fistulas (91%)
than complete excision (50%) [107]. In a retrospective
study, disorders of wound healing were seen in 20% of
patients after complete excisions and in 79% following
drainage [108].
On the other hand, surgical excision has been shown to
be superior to pharmacotherapy (clarithromycin and rifab-
utin) given for 12 weeks. The cure rates were 96% and
66%, respectively [105]. At follow-up, the aesthetic results
in surgical patients were subjectively rated better [109].
Even though surgical treatment is basically superior, it
can still be debated whether medication is more appro-
priate for lymph nodes in the parotid gland or in the region
of the submandibular gland, because of the risk of facial
nerve injury [106]. If a decision ismade for pharmacother-
apy, this should definitely take the form of a combination
therapy with at least onemacrolide antibiotic and rifampi-
cin or ethambutol for a period of up to six months [110],
[111].
Zeharia et al. reported on 92 patients who were merely
observed [112]. After purplish discolouration, there was
spontaneous rupture with a fistula for 3–8 weeks. Three-
quarters of the patients had recovered completely after
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six months, the rest after a year at the latest. These au-
thors did not report any complications. There are, how-
ever, no placebo-controlled trials on observation alone
and patients have to put up with a fistula that persists
for a relatively long time. In principle, these children also
have to be regarded as infectious.
If themicrobiology shows an infectionwithMycobacterium
tuberculosis, triple therapy with rifampicin, isoniazid and
pyrazinamide for six months is indicated [113]. In these
cases, it is important to check whether there is involve-
ment of any other organs, especially of the lungs. The
disease is notifiable and contact tracing should be per-
formed to find, inform and examine all persons who have
been in close contact with patients with open TB.
5.2.7 Other granulomatous and inflammatory
diseases
When considering granulomatous inflammation, the dif-
ferential diagnosis is important: sarcoidosis, cat-scratch
disease, Kikuchi lymphadenitis and, less commonly, tu-
laraemia and actinomycosis. In addition to demonstrating
the pathogenic organism, histology is important in the
diagnosis of persistent lymphadenopathy, in order to rule
out benign tumours andmalignant changes. Actinomycos-
is is due to gram-positive microaerophil bacteria, often
triggered by trauma or dental treatment. The salivary
glands can also be affected by the usually painless nec-
rotising infection, which often leads to fistula formation
[114]. Antibiotic therapy with Penicillin is the treatment
of choice [115].
Sarcoidosis (Besnier-Boeck-Schumann’s disease) is sel-
dom seen in childhood. Asymptomatic involvement
(swelling) of the salivary glands alone does not require
any treatment. The child should in any case be referred
for further paediatric assessment and systemic therapy
(cortisone) if necessary.
Necrotising sialometaplasia is a particular form of inflam-
mation, whichmay rarely be found in children and adoles-
cents. The World Health Organization (WHO) classifies
this condition with six other lesions of the salivary glands
[sialadenosis, oncocytic changes, benign lymphoepithelial
lesions, salivary duct cysts (retention cyst, ranula, and
dysgenetic polycystic disease), chronic sclerosing sialad-
enitis (Küttner’s tumour) and changes of the salivary
glands with HIV infection] [116]. The diseasemay appear
in all locations where there is salivary gland tissue and
very often on the hard and soft palate. Painless ulceration,
possibly caused by ischaemia followingmechanical irrita-
tion, occurs in most cases and may give rise to the suspi-
cion of malignancy [117]. In children, it may also present
as a simple swelling without any necrosis [118]. Histology
shows inflammation and granulation tissue, which heals
spontaneously after 6–12 weeks [119].
5.2.8 Juvenile recurrent parotitis
The disease is seen clinically as an acute swelling of the
affected gland, which usually affects only one side and
is associated with symptoms of varying degree. The
swelling appears independently of meals or season of
the year. There may be reddening of the skin over the
affected gland and a raised temperature or mild fever.
The swelling usually persists for 24–48 hours, but may
sometimes last for 1–2 weeks or rarely evenmonths. The
acute episodes (flares) appear punctuated by symptom-
free intervals ranging from days to years. Hyposecretion
of the gland with very viscous saliva can also be demon-
strated in the intervals and, typically, flocculent secretions
can be expressed at this time. Purulent secretion similar
to that of acute bacterial parotitis is rare and, if seen, is
found only in the acute phase.
In his review of more than 5,000 cases of chronic sialad-
enitis, Seifert reported chronic recurrent parotitis in 27%
[120]. He distinguished between a juvenile and an adult
form.
The adult form is about ten timesmore common than the
juvenile form. It affects mainly women and is usually
unilateral. Changes are seen in the distal part of the ex-
cretory duct with pronounced stenosis and dilatation.
Juvenile recurrent parotitis (JRP), which was first de-
scribed in 1909 [121], occurs between the ages of
4months and 15 years andmostly affects boys. As a rule,
there is duct ectasia of the small intraparenchymal excre-
tory ducts. Similar changes can usually also be found on
the asymptomatic side. Ussmüller divided the disease
into three stages on histological grounds (stage I: initial
inflammatory stage; stage II: advanced inflammation with
lymphatic follicles; stage III: very rare immunological end
stage with complete lymphatic transformation of the
gland) [122].
JRP is generally self-limiting, it goes into spontaneous
remission at puberty and may even completely resolve
[123]. Most patients are free of symptoms by the age
of 22 [124].
The aetiology of JRP is probably multifactorial. As early
as 1945, Hamilton Bailey proposed the presence of a
congenital or acquired abnormal dilatation of the duct
[125]. Stasis of the secretions could lead to recurrent
secondary inflammation [126]. Initial inflammation is due
to a reduced flow of saliva, resulting in changes to the
excretory duct epithelium of the salivary gland with
metaplasia, strictures, and stenosis. Metaplasia of the
duct epitheliumwould result in amoremucous secretion.
It is still not clear whether the well-documented hypose-
cretion, which can also be demonstrated in the contralat-
eral clinically normal gland, is cause or effect. Other au-
thors view the lymphocytic infiltration seen on histology
to be the cause of damage to the duct walls [127].
Weakness of the surrounding connective tissue leads to
the typical duct ectasia. This theory clearly explains the
presence of ectasia without any signs of obstruction. The
fact that changes in the ducts are also found in asympto-
matic glands also supports this assumption [124], [128],
[129].
In addition, genetic factors seem to contribute to the ae-
tiology, without any specific gene or definite correlation
having been found to date. Familial disease, in the sense
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Figure 7: Typical ‘cloud-like’ appearance of the gland in the ultrasound scans of a 22-month-old girl (a) and an 8-year-old girl
(b) with recurrent swelling of the right and left parotid glands, respectively (GLP: parotid gland; VRM: retromandibular vein; UK:
lower jaw, MD: digastric muscle, posterior belly).
of an autosomal dominant inheritance, has frequently
been reported in the literature [18]. Wittekindt et al.
published a case report relating to this, which involved
identical twins with chronic recurrent parotitis in childhood
[130]. Reid et al. reported a family where four members
had the disease and two others had asymptomatic
changes [131]. An interesting finding in JRP, as well as
in Sjögren’s disease and other conditions affecting the
oral mucosa, is that the levels of metalloproteinases
(MMP2 and MMP9) are increased in the saliva [132],
[133]. Analogous to the lymphocytic infiltration, this also
ties in with the underlying cause of JRP being autoimmune
disease [134], [135].
Besides the hypothesis of an allergic origin for the dis-
ease, postviral changes (e.g. mumps) and immune defi-
ciencies (IgG3 subclass deficiency) have been suggested
[136], but there is no concrete evidence for any of these.
Recent publications [137], [138] focussing intensively
on the composition of saliva and on analyses of the se-
cretion rate have concluded that the most likely patho-
genesis of JRP is a congenital malformation of the excre-
tory ducts, triggered by a bacterial infection. Albumin, IgA,
lactoferrin and kallikrein in the saliva were all significantly
higher than in the control group. The increase may be
due to leakage in the salivary ducts even during the
symptom-free intervals, which would also explain the
higher concentrations of serum proteins and repeated
demonstration of antibacterial substances.
Nevertheless, no acute or healed tissue damage can be
seen under the light microscope. There is, therefore, no
concrete evidence of active infection. On the other hand,
bacteria have also been demonstrated in swabs taken
between the acute episodes [124], which serve to per-
petuate the disease.
The provisional diagnosis of chronic recurrent parotitis is
based primarily on the history of repeated painful swelling
of the gland and on the clinical examination. Even in the
symptom-free interval, flocculent secretion can usually
be expressed from the excretory ducts. Diagnostic imaging
can then confirm the diagnosis. For a long time, sialo-
graphy was themethod of choice to demonstrate stenosis
and strictures in adults and duct ectasia in the juvenile
form. Pooling of contrast medium in the dilated interlob-
ular portions of the ducts is consistent with sialectasis
[139]. Even when the disease is clinically restricted to
one side, imaging usually shows contralateral involve-
ment. The extent of the radiologically detectable sialectas-
is does not correlate with the clinical symptoms [124].
However, the further development of ultrasound scanning,
MRI and CT means that conventional sialography no
longer has a place, at least in Germany. Apart from the
radiation exposure, there is a risk of contrast medium
allergy. It is also extremely difficult to perform sialography
in young children, who are generally not very cooperative.
B-mode ultrasonography is a non-invasive method that
is straightforward to use in children as well. It is easy for
experienced ENT surgeons to recognise the typical, almost
pathognomic, picture of JRP with hypoechoic and anecho-
ic areas in the parotids, which are consistent with sia-
lectasis and enlarged lymph nodes (Figure 7). Ultrasound
scanning is an excellent means of monitoring the condi-
tion and shows any parenchymal changes much more
clearly than sialography [140]. Other possible reasons
for a lymph node enlargement should, however, be con-
sidered in the differential diagnosis. A very similar picture
is seen with Sjögren’s disease and sarcoidosis, but the
clinical history and age of the patient are usually com-
pletely different [141].
MRI andMR sialography are excellent ways of visualising
salivary gland parenchyma as well as the excretory ducts.
The latter can be seen without contrast enhancement in
a special T2 weighting [130]. With alternative methods
available, however, the time and effort required for this
type of imaging in children mean that it is only worth
considering for paedriatric patients in exceptional cases.
CT is, in our opinion, not indicated because of the high
radiation exposure and little additional benefit.
Examining affected glands with the new method of
sialendoscopy shows the duct epithelium to be whitish
in colour with an atrophic appearance. Blood vessels,
usually clearly visible in the duct walls, are few or cannot
be seen at all. The actual duct ectasia is central and
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Figure 8: Endoscopy and duct irrigation with normal saline and cortisone. a) Sialendocopy of a right Stensen’s duct in a 4-year-old
patient with chronic recurrent juvenile parotitis. The illuminations shows the tip of the endoscope b) Hilum and c) distal duct
segment with the typical white changes of the duct wall without any vessels visible.
therefore not accessible with the sialendoscope. This
method alone is therefore not suitable for the diagnosis
of JRP.
To date, there is no causal treatment for the condition.
The aim of treating flares is to relieve the acute symptoms
and prevent further parenchymal damage. It is expedient
to give analgesics and antibiotics at this time. Amoxicillin
is often used in combination with a penicillinase inhibitor,
although penicillin alone, a cephalosporin or a macrolide
antibiotic should suffice, since staphylococci are not
usually encountered. It is debatable whether the natural
course of disease is actually altered by such treatment
[124], [142], [143]. Sialagogues, the local application of
heat, gland massages and probing the duct may all be
used additionally to promote the flow of saliva. There is
no firm scientific reason to give prophylactic antibiotics
to prevent acute episodes.
Radiotherapy, which was being recommended 30 years
ago, is certainly obsolete these days [144]. Diamant et
al. reported parotid duct ligation as a therapeutic alterna-
tive and occlusion of the duct with sodium amidotrizoate
(Ethibloc®) has also been described [145], [146]. Further-
more, based on the results of animal studies, the intra-
ductal administration of tetracycline has been recommend-
ed as a possible and effective measure [134]. However,
it should be noted that tetracycline in childhood may
damage the teeth and should not be given to children
below the age of 14. Maier et al. irrigated the duct with
aprotinin (Trasylol®), a kallikrein inhibitor, with short-term
success [147]. Surgical excision of the whole gland, with
all its possible complications, is seen as the last resort.
Irrigation, e.g. with normal saline or cortisone solution,
has therefore also been indicated for a long time, espe-
cially in children, as in reports on sialoraphy it had been
established that this diagnostic measure alone led to a
clear improvement in the symptoms [72], [123], [148].
A simple instillation of normal saline or penicillin into the
excretory ducts also often led to the relief of symptoms
[149].
All the invasive therapeutic options have ultimately to be
considered in the light of the fact that conservative
measures, with a watch and wait policy, result in up to
92% of all children being free of symptomswithin a follow-
up period of five years [142], [143].
Based on the results of irrigation with normal saline and
cortisone solution, a promising method of treating both
JRP and chronic recurrent parotitis in adults has been
developed in association with sialendoscopy (Figure 8).
The largest study published to date, by Shacham et al.,
reported on 65 children whose ducts had been irrigated
and dilated with about 100 ml saline solution during
sialendoscopy [150]. At the end of the procedure, the
gland was irrigated with an additional 100 mg of hydro-
cortisone via the endoscope. One inclusion criterion for
this study was at least two acute episodes within a year
– so patients with little in the way of symptoms were also
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included. At follow-up of 6–36 months, 95% of all the
patients had no symptoms after just one treatment ses-
sion. Quenin et al. reported a success rate of 87% in
10 patients with 17 treated glands [151]. Out of 14 pa-
tients inMilan who underwent a single treatment session,
five (36%) had recurrent symptoms within 20 months
and had to be treated again [152].
The first retrospective study comparing conservative
management in 21 patients with JRP and sialendoscopic
therapy in another 15 patients showed that there was a
significant improvement in both the frequency and inten-
sity of the gland swelling. The difference between the
groups was not significant, but there was a tendency to-
wards a more rapid relief of symptoms in the group
treated with endoscopy, irrigation and cortisone [72].
Definitive results can only be expected from a prospective
study.
Based on current experience and findings in the treatment
of juvenile recurrent parotitis, we recommend the follow-
ing treatment strategy [153]:
1. For mild symptoms or after a single episode: conser-
vative symptomatic treatment, antibiotic therapy with
analgesia and measures to reduce the swelling. Pro-
phylactic antibiotics are not indicated, nor are they
effective. It is worthwhile massaging the gland and
giving sialagogues in the intervals.
2. For severe symptoms and repeated episodes of
swelling: aminimally invasive procedurewith sialendo-
scopy and duct irrigation as well as the intraductal
application of prednisolone in normal physiological
saline solution (100 mg/100 ml), instilling 30–40 ml
in each gland. Children require a general anaesthetic.
3. Complete parotidectomy: as the last resort, for persist-
ent symptoms after failure of the previously men-
tioned measures or with the rare stage III disease
(immunological end stage with complete lymphatic
transformation).
5.2.9. Juvenile Sjögren’s syndrome
Sjögren’s syndrome is an autoimmune disease character-
ised by progressive lymphocytic and plasmacytic infiltra-
tion, mainly of the salivary glands and lacrimal glands.
According to Vitali et al. [154], there are six criteria for
the diagnosis of Sjögren’s syndrome: ocular symptoms,
oral symptoms, objective ocular signs (Schirmer’s test),
histologically detectable lymphocytic infiltration (>1 focus
of 50 lymphocytes/4mm2), objectively verifiable findings
in the salivary glands (<1.5 ml saliva/15 min, positive
imaging) and autoantibodies. Sjögren’s syndrome is
confirmed when at least four of these are present togeth-
er with at least positive histology or serology.
Sjögren’s syndrome occurs considerably more often in
women than men (9:1); the onset is usually between the
ages of 40 and 50. Juvenile Sjögren’s syndrome is rare
or underdiagnosed. Children and adolescents often have
predominant recurrent swelling of the parotid gland at
the onset as well as during the course of disease, whilst
ocular and oral symptoms are less common. Systemic
extraglandular manifestations (vasculitis, cryoglobulin-
aemia, autoimmune hepatitis, alveolitis, neuropathy and
B-cell lymphomas) are also seen less often during the
course of disease [155], [156]. Sjögren’s syndrome may
occasionally give rise to life-threatening situations, such
as hypocalcaemic paralysis due to renal tubular acidosis.
In addition, it may involve the central nervous system and
liver [157], [158]. A total of 81 patients aged between
four and 16 (mean 10 years of age) were reported in the
literature from 2000 to 2010 [159]. Swelling of the pa-
rotid gland was found in 65%, xerostomia in 22% and
ocular symptoms in 33% of the cases. Rheumatoid factor
was positive in 54%, SS-A (ro) in 67%, SS-B (la) in 62%
and antinuclear antibody in 72%. Nikitakis et al. gave
higher figures for xerostomia (64%) and ocular symptoms
(72%) in 95 patients studied in the period 1995–2002
[160]. Here, too, the cardinal symptom was enlargement
of the parotid gland (74%), which showed the typical
changes seen on ultrasound (Figure 9).
As the ocular and oral symptoms are not as pronounced
in children as in adult patients, the usual criteria have a
lower sensitivity to the presence of juvenile Sjögren’s
syndrome. This disease should always be considered,
however, when there is recurrent swelling of the salivary
glands without any other relevant symptoms [156]. Re-
current conjunctivitis also suggests Sjögren’s syndrome,
as do elevated amylase levels, renal tubular acidosis,
leucocytopenia, ANAs, a positive rheumatoid factor and
hypergammaglobulinaemia. Taking a cut-off of >1 focus/
4mm2, the histological findings of theminor labial salivary
glands are often negative. The sensitivity is greatly in-
creased by using a score of >0 focus/4 mm2 [161]. As in
adults, the biopsy of the parotid gland is of considerably
more diagnostic use in children. McGuirt et al. reported
on six patients: biopsy of the minor salivary glands was
negative in four of them, while parotid biopsies performed
in all patients were positive [162]. The treatment of juven-
ile Sjögren’s syndrome is largely symptomatic. As in
adults, the aims are to replace the function of the affected
glands (sialagogues, artificial saliva and tear substitutes)
and reduce the sequelae (dental care, etc.) [163]. The
management of juvenile Sjögren’s syndrome should be
discussed in detail with a paediatric or general medical
rheumatologist. To date, no studies on systemic therapy
of juvenile Sjögren’s syndrome are to be found in the lit-
erature [161], so that recourse has to be made to the
experience gained in treating adults. This is based on the
administration of corticosteroids, with cyclosporin A given
in severe cases [164]. Immunosuppressant therapy may
control the symptoms of the disease and reduce the
lymphocytic infiltration and fibrosis of the salivary glands.
Studies have shown a partial success of the anti-B-cell
antibody rituximab in adults, but, even though the circu-
lating B cells are clearly suppressed, antibody-producing
B cells remain in the glands. Rituximab is currently recom-
mended for systemic involvement [165], [166]. Gene
therapy approaches and stem cell transplantation are
still in the animal study stage [167], [168].
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Figure 9: a) Sjögren’s syndrome in a 10-year-old girl with only the symptoms of non-specific bilateral parotid swellings.
Ultrasonography showed typical hypoechoic cloud-like changes in all three major salivary glands. b) Left parotid gland (GP:
parotid gland; MM: masseter muscle, UK: lower jaw). c) Left submandibular gland (GSM LI: left submandibular gland; MMH:
mylohyoid muscle). d) Left sublingual gland (GSL: sublingual gland; UK: lower jaw; MB: floor of the mouth). In this case, the
biopsy to confirm the diagnosis was taken from the sublingual gland. e) Dense lymphocytic infiltration of the sublingual gland
parenchyma with the formation of lymphoepithelial lesions (reproduced with the kind permission of Prof. Agaimy, Department
of Pathology, and Erlangen, Germany).
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6Salivary gland tumours in children
and adolescents
6.1. Ranula
Histologically speaking and according to the WHO classi-
fiaction, ranulas and salivary gland retention cysts belong
to the group of tumour-like lesions [116]. As mentioned
previously, these lesionsmay already be present at birth.
Ranulas are extravasationmucoceles, arising from either
the ruptured and then blockedmain excretory duct of the
sublingual gland, or the numerous subsidiary ducts or
the acini [169]. In so-called plunging ranulas, the accu-
mulation of secretions extends into the soft tissues of
the neck. Pre-existing gaps in the floor of the mouth or
directly in the mylohyoid muscle predispose to these le-
sions [21], [22], [170]. Ranulas can usually be diagnosed
on visual inspection and confirmed by an ultrasound scan.
Conservative methods, including sclerosis (OK-432) and
injection with botulinum toxin A, have been described
with mixed results [171], [172], [173], [174]. Complete
excision of the sublingual gland is the surgical procedure
with the best results for recurrence rate, but it also carries
the highest risk of complications [175]. In a retrospective
study on 13 children carried out by our research group,
we also found that removal of the sublingual gland was
associated with the lowest rate of recurrence (<2%) [176].
On the other hand, extensivemarsupialisation of a ranula
is a viable alternative. The success rate is well over 85%
and the gland can still be removed later if there is a recur-
rence.
6.2 Haemangiomas and vascular
malformations
Haemangiomas are the most common vascular tumours
in childhood. Following a growth phase, the vascular
epithelium often undergoes spontaneous involution that
may last for months or even years. Haemangiomas ac-
count for almost 60% of tumours in children, of which
80% occur in the parotid gland (Figure 10) and 18% in
the submandibular region, while 2% are associated with
the minor salivary glands [114]. Vascular malformations
are pathologically anomalous structures arising from an
abnormal development and morphogenesis of arterial,
venous and/or lymphatic vessels. Section 2 of this book
takes a closer look at the classification, diagnostic
investigation and treatment of haemangiomas and vas-
cular malformations.
6.3 Epithelial salivary gland tumours
On the whole, salivary glands tumours are rare in children
and adolescents. Seifert and co-workers estimated the
incidence to be 4% in patients up to the age of 20 [177].
They reported 80 epithelial salivary gland tumours in the
register, corresponding to 2.5%. Of the 53 benign tumours
(66%), 52were pleomorphic adenomas. The 27malignant
tumours (34%) consisted of twelve mucoepidermoid
carcinomas, five acinus cell carcinomas and ten showing
other histology. Three of them, however, were adenoid
cystic carcinomas, making this type of cancer the third
most common. Cunningham et al. analysed malignant
head and neck tumours in children over a period of
20 years [178]. Malignant lymphomas were present in
60% of the 241 children with cancer. Salivary gland car-
cinomas were very rare, accounting for only 2.5% overall.
The Surveillance, Epidemiology and End Results (SEER)
database also records rhabdomyosarcomas of the salivary
glands in 8% of 113 cases [179]. Recent studies from
China, with 119 patients, confirm the distribution of the
different histological findings. Tumours were benign in
73% of the patients (n=87), with pleomorphic adenomas
of the parotid gland, submandibular gland and minor
salivary glands in all but three patients, [180]. Most tu-
mours (77%) arose after the age of ten years [181]. An
older review article [2] shows that the majority (85%) of
tumours arise in the parotid glandwith 48% of thembeing
benign; 11.7% of tumours are found in the submandibular
gland, with benign lesions accounting for two-thirds or
more [179], [182]. A further 3.2% arise in the sublingual
gland, all of which are benign. Conversely, the incidence
of malignant lesions in adults increases from the parotid
gland to the sublingual [183]. Lymphomas occur primarily
in the parotid gland, representing some 2%-5% of all
salivary gland neoplasms. About one-third of these
lymphomas are mucosa-associated lymphoid tissue
(MALT) lymphomas, another third are follicular lymphomas
and the remaining third are diffuse large cell B lympho-
mas [184].
However, when children present with a firm solid swelling
of the salivary gland, a higher suspicion of malignancy is
needed than in adults. Local pain and especially facial
palsy are further indications of possible malignancy. In
addition to the clinical examination, ultrasonography, MRI
and possibly CT are required to determine the extent of
the lesion and any local metastasis. The following section
takes a closer look at the most common benign and ma-
lignant tumours.
6.3.1 Benign epithelial tumours
A retrospective analysis of the Hamburg tumour register
with a total of 549 surgical specimens from children
showed adenomas in 47 cases (12%) [185]. 71% of these
were pleomorphic adenomas, less commonly aWarthin’s
tumour, oncocytoma, basal cell adenoma, inverted ductal
papilloma and other rare benign tumours. The pleomorph-
ic adenomasmost commonly seen usually occur between
the ages of 11 and 18. They are found in the parotid
gland, the submandibular gland and also in the minor
salivary glands [186]. Treatment of these benign tumours
consists of complete surgical resection. Tumours in the
superficial part of the parotid gland can be removed with
a superficial parotidectomy (lateral lobectomy), whilst
tumours in the deep lobe require complete parotidectomy
[187]. There is no information on how often a superficial
16/30GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2014, Vol. 13, ISSN 1865-1011
Iro et al.: Salivary gland diseases in children
Figure 10: a) Unclear findings on ultrasonography of the left parotid gland of a 12-year-old girl. MRI showed a space-occupying
lesion with high signal intensity in the T2 weighted scan and (b) a hypointense, inhomogeneous structure taking up contrast
medium in an enhanced T1 weighted scan (c). The diagnosis of an atypical pleomorphic adenoma seemed most likely. After
extracapsular dissection of the tumour (d), histology showed a cavernous haemangioma with cystic, partially thrombosed
vascular clefts with residual acini in between them (e: reproduced with the kind permission of Prof. Agaimy, Department of
Pathology, Erlangen, Germany).
parotidectomy or a extracapsular dissection is performed
at this age, although, on the basis of the currently avail-
able data, such a procedure is, in principle, also con-
sidered possible, depending on the site of the tumour
[188]. Surgery must aim for a complete resection of the
tumour, without any residual disease, whilst preserving
the facial nerve [183]. Submandibular gland resection is
indicated for tumours in the submandibular gland, with
complete local resection for the small salivary glands. As
in adults, recurrences may occur if any tumour has been
left behind and carcinomas may develop in longstanding
pleomorphic adenomas.
6.3.2. Malignant epithelial tumours of the
salivary glands
As mentioned previously, malignant epithelial salivary
gland tumours are rare, mostly presenting around the
age of 14 [189]. Girls seem to be affected more often
than boys. The site tends to be the parotid gland more
often than the submandibular gland, the sublingual gland
and the minor salivary glands [186]. In principle, all tu-
mours of the recognised WHO classification can, just as
in adults, occur histologically. Low-grade or intermediate-
grade mucoepidermoid carcinomas are the malignant
tumours most frequently described in childhood [190],
followed by acinus cell carcinomas (Figure 11) and aden-
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oid cystic carcinomas. These three types of cancer ac-
count for 80–90% of malignant salivary gland tumours
in children and adolescents. Adenocarcinomas, basal cell
carcinomas and squamous cell carcinomas of the salivary
glands are less common.
Figure 11: A 12-year-old boy with a mobile, slowly growing
space-occupying lesion in the right parotid gland (arrow). After
parotidectomy, histology showed an acinus cell carcinoma
(image kindly supplied by Prof. M.B. Gillespie, University of
South Carolina, Charleston, USA)
The treatment of choice is surgical removal of the tumour
with a superficial or total parotidectomy, combined if ne-
cessary with neck dissection [114]. As for adenomas,
total parotidectomy is preferred for tumours in the deep
lobe [191]. But it is well known that the extent of the re-
section impacts the recurrence rate. A study from the
Mayo Clinic found the recurrence rate ofmucoepidermoid
carcinomas to be 48% after simple enucleation, 31%
after lateral parotidectomy and 0% after total parotidec-
tomy [192]. In view of these results, it can certainly be
argued that total parotidectomy should be performed for
all parotid gland malignancies in childhood.
When the facial nerve has been infiltrated by tumour, it
must also be resected to obtain an R0 resection and ap-
propriate rehabilitation measures carried out [193]. Re-
moval of the gland, with or without neck dissection, is
indicated for cancer of the submandibular or sublingual
gland. Malignancy of the minor salivary glands requires
complete resection (clinically extending into healthy tis-
sue). Neck dissection in children with salivary gland can-
cer can be considered in the sameway as for adults. Such
a dissection is indicated whenever abnormal lymph nodes
are picked up on clinical examination or imaging. Elective
neck dissection should be carried out whenever there
are undifferentiated or large tumours (T3–4) and in cer-
tain individual cases [32], [194]. Given the 36% incidence
of cervical node metastasis (N+) [191], with predomin-
antly poorly differentiated tumours, it is our opinion that
neck dissection can be considered as a basic elective
procedure.
Postoperative radiotherapy for children is, of course, in-
dicated in selected cases only (R1 resection, perineural
invasion, advanced tumour stage, and poorly differenti-
ated tumour) [195]. Nevertheless, it must be remembered
that radiotherapy in children may affect growth of the
skull bones and even cause osteoradionecrosis, trismus,
dental problems, visual disorders and, in particular, radi-
ation-induced secondmalignancies [191]. The indication
for chemotherapy is found mainly in palliative situations
or following recurrence, especially when surgery and ra-
diotherapy are no longer possible [196].
Kupferman et al. carefully analysed the risk factors and
the prognosis of childhood epithelial salivary gland cancer
in a large population of 61 patients over a long follow-up
period (median: 114months) [191]. They found that 72%
of the cases had T1 or T2 tumours and only 7% were
classed as T4. Metastasis to the cervical lymph nodes
(N+) was present in 36% of the cases. The five- and ten-
year overall survival rates were 93% and 84%, respect-
ively, with figures of 85% and 80% for disease-free surviv-
al. Seven patients died, five of them from the primary
cancer. Univariate analysis of their data showed that pa-
tients aged more than 14 years, of non-Caucasian des-
cent, with undifferentiated tumours, and with perineural
invasion had a significantly worse disease-specific survival
rate. The age, histology, ethnic origin and positive cervical
lymph nodes were statistically related to poorer overall
survival. Mucoepidermoid carcinomas have a relatively
favourable prognosis, even when they arise as second
malignancies (e.g. following treatment of lymphoma) with
a 5-year survival rate of almost 94% or even better [197],
[198]. A similarly good outcome, with a disease-specific
survival of 88.4%, is also achieved with cancer of the
minor salivary glands, if small, well-differentiated tumours
are completely resected [199]. On the other hand, the
survival rate falls with the corresponding risk factors, e.g.
to 30–50% with undifferentiated tumours. Just like adult
patients with such cancer, these children have to be fol-
lowed up long-term over 10–20 years [200].
7 Systemic causes of salivary gland
swelling
Systemic diseases, whose pathogenesis is not primarily
related to salivary gland disease, may also cause swelling
of the salivary glands in children. Today, many of these
diseases can be treated successfully, so that changes in
the salivary glands may not be seen so often. These dis-
eases include hormone disorders such as hypothyroidism,
diabetes mellitus and disorders of the pituitary gland
[201]. The submandibular gland in particular may be
enlarged in cystic fibrosis [202]. Nutritional disorders
(obesity, malnutrition, hyperlipoproteinemia and vitamin
deficiencies) may cause salivary gland enlargement.
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Bulimia or anorexiamust also be considered, particularly
in adolescents with bilateral parotid swellings. The actual
pathological mechanism for the swelling is not known.
Ultrasound scans show homogeneously enlarged glands
similar to those seenwith sialadenosis [203]. Medications
responsible for drug-induced enlargement of salivary
glands are not often prescribed for children.
8 Sialorrhoea
Sialorrhoea (excessive salivation or drooling) impacts
strongly on the mental state of the patient and is there-
fore a medical condition that needs to be clarified and
treated. Sialorrhoea carries a social stigma, due to the
impossibility of holding the saliva in the mouth and is
usually found in association with an underlying neurolo-
gical disease. In the long term, drooling leads to a consid-
erable reduction in the quality of life of the affected chil-
dren and their families.
The indication for treatment depends on the quantity of
saliva produced and the individual situation of the child
or adolescent. Patients with mild sialorrhoea, but of nor-
mal intelligence and perhaps with a slight speech imped-
iment, feel socially incompetent and rejected. At the
other end of the scale are children with physical and
learning disabilities, who have profuse sialorrhoea. They
wear 10–15 bibs a day to catch the saliva, need frequent
changes of clothes, and often need to be looked after in
care facilities. These patients dribble all the time, and
over everything. Consequently, they are often socially
isolated and receive less loving care and attention.
The complexity of sialorrhoea and the many possibilities
for treatmentmake interdisciplinary management essen-
tial. A team consisting of an ENT surgeon, dentist and
orthodontist as well as amaxillofacial surgeon, neurologist
or paediatric neurologist and speech-language therapist
should agree on the best possible treatment. Together,
they must consider whether spontaneous improvement
is likely and, if not, they must decide which therapeutic
modality to use, in particular, whether surgery is required
[204], [205].
Increased salivation, in the sense of sialorrhoea, is
physiological up to the age of four years. Excessive sali-
vation in children over the age of four, who are awake,
must, however, be considered pathological.
The most common reason for drooling is a neurological
disorder, with an incidence of 10% to 30% [206]. Peripher-
al disorders of the trigeminal or facial nerves can also
lead to drooling. With neurological disorders, difficulty in
swallowing is a much more prominent feature than the
hypersecretion of saliva. A lack of lip closure is a prime
feature [207]. Centrally regulated sialorrhoea may be
caused by raised intraluminal oesophageal pressure, but
is far more often due to interruption of the first (oral)
phase of swallowing. Uncoordinated movements of the
tongue impede the transport of saliva from the mouth to
the oropharynx. Sialorrhoea has been studied particularly
well in childrenwith Down’s syndrome. Generalmuscular
hypotonia and relative macroglossia with a wide mouth
opening have a deciding aetiological role [205].
Drug-induced hypersalivation, especially due to neuro-
leptic agents, can be distinguished from sialorrhoea of
neurological origin. Alpha-adrenergic and muscarinic re-
ceptors in particular are involved in the pathophysiology
of neuroleptic-induced salivation [208].
Idiopathic hypersalivation is another form of sialorrhoea
of unknown origin. A study by Johnson et al. showed that
children who are developing normally may also show
delay in saliva control. This problem is usually self-limiting
without any treatment, as the child continues to develop
[209].
Besides the obvious causes, important cofactors impact-
ing on sialorrhoea include the current emotional status,
ability to concentrate, disorders of occlusion, tooth dam-
age and posture. Dental or gingival damage naturally in-
creases salivation, whilst inclining the head forward obvi-
ously encourages saliva to flow out of the mouth under
the force of gravity.
In addition, patients with difficulty in nasal breathing and
wide-open mouths tend to salivate more. Treatment with
anticonvulsants also promotes hypersalivation [205].
Gastro-oesophageal reflux may be a problem in children
and it has been suggested that reflux may induce hyper-
stimulation of the salivary glands with increased saliva
production [204]. Even though an effect on drooling has
not yet been confirmed for anti-reflux therapy, such
treatment has led to considerable improvement in a few
cases [210].
A rough estimate of the severity of the sialorrhoea is the
minimum required to assess and compare different
therapeutic approaches and outcomes. The problemwith
sialorrhoea is that it undergoes extreme temporal vari-
ation. Blasco et al. divided the various methods for
quantifying the degree of drooling into three categories
[210]:
1. Basic clinical estimation (e.g. the number of bibs or
T-shirts required)
2. Drooling severity scales and frequency based on sys-
tematically timed observations [211].
3. Volumetric measurement of saliva for absolute
quantification of the saliva flow using special external
or intraoral collection devices [212], [213]
However, none of these different methods can replace
the long-term observations of the parents or carers. The
best semiquantitative measure is the number of bibs or
T-shirts required during the course of a ‘typical day’, a
‘bad day’ or a ‘good day’.
Interestingly, numerous surgical procedures have been
reported in the literature of English-speaking countries,
while conservative treatment is preferred in German and
European sources. The problems of drooling also seem
to be perceived differently in different societies.
Before beginning any specific treatment of sialorrhoea,
the potentially exacerbating factors first need to be cor-
rected. Dealing with tooth decay, resecting hypertrophic
tonsils or correctingmalocclusion often leads to a distinct
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improvement in the symptoms. The treatment of sialor-
rhoea always requires interdisciplinary cooperation
between dentist, ENT surgeon, orthodontist, maxillofacial
surgeon and neurologist or paediatric neurologist.
8.1 Conservative therapeutic approaches
Behavioural modification and biofeedback therapy
These therapeutic methods aim to trigger swallowing in
response to an auditory signal [214]. In a study on EMG
biofeedback, a significant reduction in salivary flow with
a simultaneous slightly increased rate of swallowing could
be achieved. The success of the method depends on
improved coordination during the oral phase of swallow-
ing, but it is very time consuming. Nevertheless, Rapp
reported a sustained benefit in children with a mental
age of between 18 months and 8 years [215].
Oral-motor therapy and orofacial regulation therapy
In 1978, McCracken reported on the treatment of three
cases using a sensorimotor technique. Vibration was
applied to the masseter as well as to the anterior belly
of the digastric muscle and the lip area for two to three
minutes [216]. Harris and Dignam also found this thera-
peutic technique to be successful [213]. However, the
available reports on thismethod are ultimately concerned
with small patient groups only. In Germany and South
America, the literature focuses on the Castillo-Morales
concept of orofacial regulation therapy [217], [218],
[219], [220]. This method essentially involves the applic-
ation of acrylic plates in the region of the palate and oral
vestibule of the upper and lower lips, which function as
active components stimulating the intra- and circumoral
muscle, in combination with oral and facial physiotherapy.
This treatmentmethod can be started in infants as young
as six weeks old. Its effects have been monitored partic-
ularly well in several studies on patients with Down’s
syndrome. Here, improvement was seen in the symptoms
of hypotonia with the resulting optimisation of swallowing
and expression [218]. Furthermore, it reduced tongue
protrusion with improved lip closure. Similar observations
have also beenmade in children with central motor injury.
An improvement in the spontaneous position of the
tongue, coordination of tongue movements, eating,
speech development,and drooling was seen in almost
half of the cases (n=71) [218], [220].
In summary, it can be said that although orofacial therapy
at least reduces drooling, it can rarely return salivation
to normal [205]. Treatment should always start before
the age of four, otherwise the palatal stimulating plate is
not tolerated and there is no guarantee of success. It is
not known whether the stimulating plate is better used
alone or with the additional physiotherapy [204].
Speech therapy
Even though experimental attempts have been made to
reduce drooling with speech therapy, it seems to be too
time-consuming and is only successful with continuous
application [216].
8.2. Medication for sialorrhoea
The basis of many pharmacotherapeutic approaches to
drooling is an anticholinergic effect. One of the oldest
and best-known active substances is scopolamine, a
cholinergicmuscarinic receptor-antagonist, which causes
a significant reduction in salivation, even in comparison
with atropine [221]. Giving medication to children and
adolescents has to be considered very carefully and is,
at most, indicated in exceptional cases for a short time
only. The best-known method of administration is the
Scopodermpatch (Scopoderm TTS®), which can be affixed
directly to the skin behind the ear, after the area has
been cleansed with 70% alcohol. The patch can be left
in situ for up to four days after which time it is replaced
with a new patch. The onset of action is about 15minutes
after applying the patch [222]. Very good results have
been achievedwith Scopodermpatches in adults. Adverse
effects, such as local allergic reactions, acute psychotic
and confusional states, dry mouth, constipation, urinary
retention, reduced sweating and flushing, may occur.
Hypertension and glaucoma are relative contraindications
[205].
An important recent addition is the use of botulinum
toxin A to inhibit salivary gland secretion. Botulinum toxin
inhibits the reuptake of the neurotransmitter acetylcholine
from the synaptic cleft, thereby blocking signal transmis-
sion and reducing saliva production; this, in turn, leads
to a considerable reduction of drooling [223], [224],
[225], [226], [227], [228], [229]. However, it must be
remembered that treating hypersalivation with botulinum
toxin is currently off-label use, i.e. using an approved
medicinal product for an indication not included in its
marketing authorisation. In terms of prescribing freedom,
however, the medicinal product may also be used for a
non-approved indication when this is justified andmedic-
ally necessary. On the basis of existing studies, its use in
the salivary glands falls into this category. According to
Ellies et al., the best way is to inject the toxin, under ultra-
sound guidance, into both parotid glands (21 units of
Botox® each side) and both submandibular glands
(10 units of Botox® each side). Improvement can already
be seen three days after the injection [224], [225], [226].
Bothwell et al. used botulinum toxin A in a population of
children with sialorrhoea associated with various neuro-
logical diseases. They injected 5 units of botulinum toxin
into the parotid gland. All patients had a reduced inci-
dence of hypersalivation after four weeks. Eight of the
nine patients also showed a reduction in the objectively
measured salivary flow; 55% of the parents were of the
opinion that the treatment was successful. The reported
adverse reactions included difficulty chewing, dry mouth,
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Figure 12: Boy with persistent drooling despite four sessions of botox therapy in both parotid and submandibular glands and
rerouting the submandibular ducts into the tonsillar fossa (a). Clear improvement was seen only after bilateral submandibular
gland resection (b).
and transient weakness of jaw closing – the last probably
due to inaccurate injection into the masseter muscle
[223]. The possibility of transient facial paresis should
also bementioned, although this has not been described
in the literature with regard to the use of botulinum toxin.
The effects of botulinum toxin A last 8–16 weeks and
then the injections have to be repeated. Compared with
anticholinergic medication (see above) the success rate
is about the same.
8.3 Surgical treatment of sialorrhoea
Despite conservative methods as well as the use of
medication and even acupuncture, surgical procedures
may be indicated for drooling because of adverse drug
reactions or treatment failure [230], [231], [232].
These operations essentially aim to reduce saliva produc-
tion, change the outflow of saliva or involve a combination
of the two. Transtympanic neurectomy of the tympanic
nerve [233] often leads to recurrence and especially to
a loss of taste sensation or possibly even to xerostomia
[234]. For this reason, it is nowadays no longer per-
formed. Distortion or even loss of the sense of taste is
particularly serious for children and those with mental
impairment, as oral sensations are often the only pleas-
ures in their lives.
Reduction in saliva production can obviously be achieved
by resecting the gland. Here, the simplest solution for
pronounced drooling is certainly to remove both sub-
mandibular glands (Figure 12).
Simple ligation of the parotid and/or submandibular ducts
have been described [235]. Instead of using ligatures,
one research group occluded the parotid duct using
Nd:YAG laser impulses, resulting in stenosis. With this
procedure, they achieved symptomatic improvement in
more than 90% of the 48 patients [236]. However, a
manipulation of the parotid duct on its own is somewhat
disputed in the literature, as the parotid gland produces
only a small proportion of the saliva at rest, even though
it is of greater importance when secretion is stimulated
[205]. Other surgical techniques consist of rerouting the
excretory ducts. For this, the parotid ducts and possibly
also the submandibular ducts are dissected out from
their usual anatomical positions and reimplanted in the
tonsillar fossa. In 1967, Wilkie was the first to propose
the procedure, which was subsequently named after him.
The parotid ducts were implanted in the tonsillar fossae,
in order to trigger a direct swallowing reflex on salivation
[237]. Wilkie and Brody modified the procedure in 1977,
by removing the submandibular glands during the same
operation. Tonsillectomy is also carried out as part of the
procedure, in order to prevent stenosis and recurrent in-
fection of the excretory ducts or salivary glands [238],
[239]. Even the rerouting of the parotid duct with autolo-
gous venous interposition grafts has been tried as a
variation of Wilkie’s procedure [240]. Rerouting of the
submandibular duct into the tonsillar fossa has also been
described, a procedure that is associated with the risk of
a ranula developing [241], [242], [243].
One obvious disadvantage of these operations is that the
patient has to be admitted to hospital. In addition, there
is a risk of a branchial cyst developing, as well as severe
caries [243].
Rerouting the excretory duct into the tonsillar fossa is
contraindicated in patients being aspirated. Figures from
67% to more than 90% have been reported for the suc-
cess rates of the surgical procedures.
9 Parotidectomy in children:
indications and complications
Overall, parotidectomy is very rarely indicated in children.
In their analysis of 22 parotidectomies (six total), Xie and
Kubba [244] demonstrated the different indications very
well. Congenital abnormalities, atypical mycobacterial
infections and tumours were each responsible for about
one third of the patients requiring surgery. This is very
different from the reasons seen in adults [32], [245].
Typical complications, such as transient or persistent fa-
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Figure 13: Permanent facial palsy (House-Brackman VI) after
resection of a fistula in the right parotid gland, in a one-year-old
patient operated on elsewhere. Revision surgery was performed
with nerve interposition grafting.
cial palsy (Figure 13) and Frey’s syndrome, occur about
as frequently as in adult patients. We recommend the
use of facial nerve monitoring and nerve stimulation
during surgery in children. It is important to remember
that the facial nerve may lie much more laterally in chil-
dren than in adults, as the mastoid cells are not yet fully
developed. In proportion to the surrounding structures,
the nerve is even slightly larger in young children [2],
[246]. There are no contraindications to this procedure.
Transient facial weakness has been reported in 36% and
persistent palsy in 11% of lateral or total parotidectomies
[191]. Other authors give figures of 23% to 50% for
transient paresis and complete recovery with time. The
incidence of short-term facial nerve weakness is higher
with total than with superficial parotidectomy (25% vs
16%) [32]. A mild Frey’s syndrome that did not require
treatment was found in 19% of children following lateral
parotidectomy [183], [244]. Hypertrophic scarring requir-
ing treatment (14%) seems to be more common in chil-
dren than in adults. Treatment is usually intralesional in-
jection of steroids. One study found the recurrence rate
of pleomorphic adenomas in children to be 20% [2]. The
authors attributed this to the smaller anatomical struc-
tures, which make capsular rupture and tumour seeding
more likely. In contrast, Malone and Baker [247] found
no recurrence in their patients after up to 20 years’ follow-
up.
In principle, surgeons must be aware of the special fea-
tures of parotidectomy in childhood that have been
mentioned and discuss them in detail with the parents
as well as with the children, if they are older. The surgeon
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